Novavax expands COVID-19 vaccine study to include children aged 12 to 17

The global fight against the COVID-19 pandemic has been marked by the development and distribution of various vaccines. As the vaccination campaigns continue worldwide, the focus has shifted to include younger age groups, particularly children aged 12 to 17. One notable player in this endeavor is Novavax. In response to growing concerns about the virus’s impact on adolescents, Novavax has expanded its COVID-19 vaccine study to include children aged 12 to 17. Expanding the scope Novavax has made significant strides in its vaccine research and development. While their vaccine has been authorized for emergency use in various countries for adults, the company recognizes the importance of extending protection to younger age groups.